[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Esperion Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100447193","bempedoic-acid-pregnancy-surveillance-program-100447193",false,"NCT05103254","Bempedoic Acid Pregnancy Surveillance Program","A Post-marketing, Long-term, Observational, Descriptive Study to Assess the Risk of Pregnancy and Maternal Complications and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Women Exposed to Bempedoic Acid or Bempedoic Acid\u002FEzetimibe Fixed Combination Drug Product (FCDP) During Pregnancy","Inclusion Criteria:\n\nExposure to at least 1 dose of bempedoic acid or bempedoic acid\u002Fezetimibe FCDP at any time during pregnancy (from first day of last menstrual period \\[LMP\\] to pregnancy outcome\n\nExclusion Criteria:","FEMALE","18 Years",{"count":19,"type":20},20,"ESTIMATED","OBSERVATIONAL","Bempedoic acid pregnancy surveillance program",[24,25],"Pregnancy","Hyperlipidemias",[27],"bempedoic acid","RECRUITING","2024-05-15",{"date":31,"type":32},"2024-05-17","ACTUAL",{"date":34,"type":32},"2021-09-01",{"date":36,"type":20},"2032-05",{"name":38,"class":39},"Esperion Therapeutics, Inc.","INDUSTRY",""]